These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34854794)

  • 21. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
    Singh VK; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical countermeasures for radiation induced health effects: report of an Interagency Panel Session held at the NASA Human Research Program Investigator's Workshop, 26 January 2017.
    Carnell LS; Homer M; Hoots K; Meeks H; Prasanna PGS; Rios C; Simonsen LC; Taliaferro LP; Wathen LK
    Int J Radiat Biol; 2021; 97(sup1):S117-S124. PubMed ID: 31490103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The NIAID Radiation Countermeasures Program business model.
    Hafer N; Maidment BW; Hatchett RJ
    Biosecur Bioterror; 2010 Dec; 8(4):357-63. PubMed ID: 21142762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation combined injury: overview of NIAID research.
    DiCarlo AL; Ramakrishnan N; Hatchett RJ
    Health Phys; 2010 Jun; 98(6):863-7. PubMed ID: 20445395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twenty five years of the National Academy of Medical Sciences of Ukraine - progress and priorities for future of radiation medicine and biology.
    Bazyka D
    Probl Radiac Med Radiobiol; 2017 Dec; 22():10-14. PubMed ID: 29286493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Considerations of Medical Preparedness to Assess and Treat Various Populations During a Radiation Public Health Emergency.
    Winters TA; Cassatt DR; Harrison-Peters JR; Hollingsworth BA; Rios CI; Satyamitra MM; Taliaferro LP; DiCarlo AL
    Radiat Res; 2023 Mar; 199(3):301-318. PubMed ID: 36656560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Celebrating 60 Years of Accomplishments of the Armed Forces Radiobiology Research Institute1.
    Bene BJ; Blakely WF; Burmeister DM; Cary L; Chhetri SJ; Davis CM; Ghosh SP; Holmes-Hampton GP; Iordanskiy S; Kalinich JF; Kiang JG; Kumar VP; Lowy RJ; Miller A; Naeem M; Schauer DA; Senchak L; Singh VK; Stewart AJ; Velazquez EM; Xiao M
    Radiat Res; 2021 Aug; 196(2):129-146. PubMed ID: 33979439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency: Lessons Learned from Biological Threats and other Disease Treatments.
    DiCarlo AL; Cassatt DR; Dowling WE; Esker JL; Hewitt JA; Selivanova O; Williams MS; Price PW
    Radiat Res; 2018 Dec; 190(6):659-676. PubMed ID: 30160600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency.
    DiCarlo AL; Horta ZP; Aldrich JT; Jakubowski AA; Skinner WK; Case CM
    Radiat Res; 2019 Jul; 192(1):99-120. PubMed ID: 31081742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Growth Factors and Cytokines to Treat Injuries Resulting from a Radiation Public Health Emergency.
    Horta ZP; Case CM; DiCarlo AL
    Radiat Res; 2019 Jul; 192(1):92-97. PubMed ID: 31063041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing polyphenolic acetates as radiation countermeasure agents: current status and future perspectives.
    Venkateswaran K; Shrivastava A; Prasad AK; Parmar VS; Dwarakanath BS
    Drug Discov Today; 2020 Apr; 25(4):781-786. PubMed ID: 32062010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on romiplostim for treatment of acute radiation syndrome.
    Singh VK; Seed TM
    Drugs Today (Barc); 2022 Mar; 58(3):133-145. PubMed ID: 35274632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.
    Singh VK; Romaine PL; Newman VL; Seed TM
    Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges and Strategies in the Development of Radiation Biodosimetry Tests for Patient Management.
    Satyamitra M; Reyes Turcu FE; Pantoja-Galicia N; Wathen L
    Radiat Res; 2021 Nov; 196(5):455-467. PubMed ID: 34143223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Strategic National Stockpile: identification, support, and acquisition of medical countermeasures for CBRN incidents.
    Neumeister SM; Gray JP
    Toxicol Mech Methods; 2021 May; 31(4):308-321. PubMed ID: 33208007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES BIODOSIMETRY AND RADIOLOGICAL/NUCLEAR MEDICAL COUNTERMEASURE PROGRAMS.
    Homer MJ; Raulli R; DiCarlo-Cohen AL; Esker J; Hrdina C; Maidment BW; Moyer B; Rios C; Macchiarini F; Prasanna PG; Wathen L
    Radiat Prot Dosimetry; 2016 Sep; 171(1):85-98. PubMed ID: 27590469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The National Institutes of Health Chemical Countermeasures Research Program (NIH CCRP): A collaborative opportunity to develop effective and accessible chemical medical countermeasures for the American people.
    Yeung DT; Harper JR; Platoff GE
    Drug Dev Res; 2020 Dec; 81(8):907-910. PubMed ID: 32573018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop.
    DiCarlo AL; Tamarat R; Rios CI; Benderitter M; Czarniecki CW; Allio TC; Macchiarini F; Maidment BW; Jourdain JR
    Radiat Res; 2017 Aug; 188(2):e54-e75. PubMed ID: 28605260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Scientific research and product development in the United States to address injuries from a radiation public health emergency.
    DiCarlo AL
    J Radiat Res; 2021 Sep; 62(5):752-763. PubMed ID: 34308479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Where are the medical countermeasures against the ARS and DEARE? A current topic relative to an animal model research platform, radiation exposure context, the acute and delayed effects of acute exposure, and the FDA animal rule.
    MacVittie TJ
    Int J Radiat Biol; 2023; 99(7):994-1008. PubMed ID: 36811500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.